Cure8 research brief
Patients and clinicians using vedolizumab may be interested because the review links higher trough concentrations to better remission outcomes—most convincingly for endoscopic remission in UC—and provides descriptive trough ranges that some groups are using as potential targets.
Patients on vedolizumab (patients-on-biologics), gastroenterology clinicians considering therapeutic-drug-monitoring, and researchers designing interventional TDM trials.
This review combined 23 studies (6,753 patients) and found that higher VDZ trough concentrations were most strongly associated with endoscopic remission in UC; pooled mean differences favored higher levels in UC endoscopic remission and in clinical remission for both UC and Crohn's disease (CD).
The authors present descriptive maintenance-target ranges (≈≥13–15 µg/mL for UC and ≈≥10–12 µg/mL for CD) based on pooled remission-associated concentrations.
The authors emphasize that most included data are cross-sectional or observational, so associations could reflect reverse causation (remission leading to higher drug levels) rather than a causal dose–response. They state that prospective interventional trials are needed before recommending proactive therapeutic drug monitoring (TDM) for vedolizumab.
If you are on vedolizumab or manage patients on it, this review synthesizes current evidence linking trough levels with remission but does not provide definitive proof that changing doses to hit targets will improve outcomes.
This article is an abstract-level synthesis (systematic review and meta-analysis) of mostly observational studies. The authors caution that cross-sectional associations do not prove that raising vedolizumab doses will produce remission; randomized prospective trials are needed.
The summary and target ranges are drawn from pooled observational data, not from interventional trial results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
